Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)
**China’s New CAR-T Therapy: Bringing New Hope for Acute Myeloid Leukemia (AML)**
AML
#CLL1CART #AML #Leukemia #CART #CARTtherapy #AcuteMyeloidLeukemia #CLL1 #CD371
In recent years, China’s rise in the field of medical innovation has been remarkable, especially with breakthroughs in cancer and hematologic malignancy treatments that are drawing global attention. Today, we are introducing a cutting-edge treatment from China—donor-derived CLL-1 CAR-T therapy, which offers new hope for adults with relapsed or refractory acute myeloid leukemia (AML). This advanced therapy provides a novel option when conventional treatments prove ineffective.
In AML treatment, the CLL-1 antigen (also known as CD371) is an ideal target, as it is highly expressed on AML leukemic stem cells but not on healthy hematopoietic stem cells. CAR-T therapy targeting CLL-1 can precisely attack AML cells while minimizing effects on healthy immune cells, offering a specific treatment choice with fewer side effects.
### Success Cases of Donor-Derived CLL-1 CAR-T Therapy in China
A 17-year-old Chinese high school student successfully underwent donor-derived CLL-1 CAR-T treatment, providing critical evidence of the therapy’s potential. After being diagnosed with AML, he went through multiple rounds of chemotherapy and autologous stem cell transplantation, but frequent relapses made treatment exceedingly difficult. Due to a lack of sufficient lymphocytes for autologous CAR-T therapy, doctors decided to use donor-derived CLL-1 CAR-T therapy, followed by an allogeneic stem cell transplant.
– **Treatment Process:** After successfully collecting donor lymphocytes and completing preconditioning, the patient received two CAR-T cell infusions. Initially, he experienced mild fever, a common reaction to cytokine release syndrome (CRS), but his condition soon improved significantly.
– **Remarkable Effectiveness:** On the eighth day post-infusion, bone marrow testing showed no cancer cells, lab results returned to normal, and he successfully completed the allogeneic stem cell transplant. During follow-up, his condition remained stable without signs of relapse, and he has since returned to school, resuming a normal life.
### The Breakthrough Significance of China’s CAR-T Therapy in Global AML Treatment
Chinese experts believe that China’s donor-derived CLL-1 CAR-T therapy has significant value in AML treatment, particularly for patients who are unable to undergo conventional CAR-T therapy due to insufficient lymphocytes. Allogeneic stem cell transplantation is an effective AML treatment, but the high relapse rate remains challenging. Introducing CAR-T therapy before transplantation can significantly reduce the risk of relapse, extend patient survival, and improve quality of life. Most patients tolerate the therapy well, with only mild adverse reactions, such as CRS and minor neurotoxicity, and long-term follow-up shows durable effectiveness.
China’s breakthrough in CAR-T therapy for AML provides a new model for leukemia treatment worldwide. China’s donor-derived CLL-1 CAR-T therapy not only brings hope to patients but also offers valuable insights to the global medical community in leukemia treatment. As medical technology advances, Chinese CAR-T therapy will bring benefits to more leukemia patients, helping them achieve long-term survival and improved quality of life.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of Advanced Medicine in China for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#MedicalInnovation #CancerTreatment #HematologicMalignancy #LeukemiaTreatment #ChinaBiotech #CellTherapy #StemCellTransplant #GlobalHealth
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
A CAR-T Success Story in China: A Beacon of Hope for Acute Myeloid Leukemia(AML) Patients
A CAR-T Success Story in China: A Beacon of Hope for Acute Myeloid Leukemia(AML) Patients
patient story
#CAR-T #AcuteMyeloidLeukemia #AML #ChinaHealthcare #patientstory #CD33
In the field of cancer treatment, China’s medical advancements have brought new therapeutic opportunities for patients, especially with CAR-T cell therapy. Although CAR-T has achieved significant success in treating lymphoid tumors, its application in myeloid malignancies, particularly acute myeloid leukemia (AML), has been challenging. However, a recent successful case of CD33 CAR-T therapy in China has ignited hope for patients with refractory relapsed AML.
#### Patient Story
The patient is a 25-year-old Chinese male who initially sought medical attention due to dizziness and fatigue. He was eventually diagnosed with high-risk AML associated with the DEK::CAN fusion gene, which has a very poor prognosis. Despite some initial effectiveness of chemotherapy and undergoing allogeneic hematopoietic stem cell transplantation (Allo-HSCT), the disease relapsed six months later.
After multiple attempts with targeted therapies and donor cell infusions, the results remained unsatisfactory. Just when traditional treatments seemed ineffective and hope was dwindling, the patient sought out my Advanced Medicine in China team.
#### Breakthrough Treatment: China’s CD33 CAR-T
The patient received a consultation and treatment from the medical experts of my Advanced Medicine in China team. After admission and initial preparations, he underwent CD33 CAR-T therapy, an innovative treatment specifically targeting myeloid tumors. After three days of chemotherapy conditioning, the CAR-T cells were infused on day 11. Although there was a mild fever during this period, the patient experienced no significant discomfort. Subsequently, the bone marrow examination revealed astonishing news: leukemia cells had completely disappeared, and the DEK::CAN fusion gene was nearly undetectable, indicating that the disease was in a state of complete remission.
Despite experiencing a lung infection during treatment, the patient’s condition improved after antibiotic therapy. He did not suffer from severe side effects such as persistent cytopenia, and his blood parameters returned to normal. He was ultimately discharged smoothly.
#### Sustained Remission and a Bright Future
Two months after receiving CD33 CAR-T cell therapy, the patient remains in a state of complete molecular remission, with normal blood counts and a significant improvement in quality of life. This case demonstrates that CAR-T therapy not only successfully controlled refractory relapsed AML but also significantly enhanced the patient’s chances of survival and quality of life.
#### A New Chapter for CAR-T Treatment of AML in China
This case highlights China’s innovative capabilities in the field of CAR-T therapy, particularly in the treatment of myeloid malignancies. For AML patients like this young man who have faced multiple treatment failures, China’s CAR-T therapy undoubtedly brings new hope.
Although global CAR-T therapies for myeloid malignancies are still in their infancy, this groundbreaking advancement in China indicates that CAR-T therapy is poised to become a crucial method for treating refractory relapsed AML in the future. As research deepens and technologies mature, this therapy may save more patients in dire circumstances.
China’s leading position in CAR-T treatment is bringing new hope to patients worldwide. For all AML patients, this story proves that the path to a brighter future has been paved, and for many, it begins with China’s CAR-T therapy.
To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!
WhatsApp: Https://wa.me/+8613717959070
Email: doctor.huang@globecancer.com
#CancerTreatment #InnovativeTherapy #PatientSuccess #MedicalAdvancements #HopeInHealthcare #Immunotherapy
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78
Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79
Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML
Chinese Research Team New Treatment Shows Promise: CD7 CAR-T Cell Therapy for Relapsed/Refractory AML
A recent clinical trial has unveiled a new prospect for treating relapsed/refractory acute myeloid leukemia (AML). The study delved into the safety and efficacy of a natural selection CD7 CAR-T cell (NS7 CAR-T cell) in treating CD7+ relapsed/refractory AML patients.
The research involved 10 cases of CD7+ relapsed/refractory AML, where 30% of AML patients expressed CD7. Following treatment with NS7 CAR-T cell infusion, the results showed that within 4 weeks post-infusion, 70% of patients achieved complete bone marrow remission (CR), with 6 patients achieving a deep remission at the level of minimal residual disease (MRD). Notably, the loss of CD7 was identified as a primary reason for non-response in some patients.
The study also indicated that the majority of patients (80%) experienced mild cytokine release syndrome (CRS) post-infusion, with no observed neurotoxicity.
Furthermore, for select patients, continuing with a second allogeneic hematopoietic stem cell transplantation post NS7 CAR-T cell treatment resulted in promising long-term outcomes. However, further exploration is required for patients who did not undergo consolidative transplants to enhance treatment efficacy.
Professor Lu Peihua(Lu Daopei Hospital) remarked that this study highlights the potential of CD7 CAR-T cells as a bridging therapy before transplantation, demonstrating preliminary therapeutic efficacy for relapsed/refractory AML patients. Nevertheless, a comprehensive evaluation of its efficacy requires a larger sample size and longer-term follow-up.
This preliminary study represents a significant advancement in the field of AML treatment, but collaborative efforts and more research are still necessary. Looking ahead, we anticipate further studies and treatment outcomes to bring more beneficial therapeutic options for the long-term survival of patients, supported by a broader patient cohort and collaborative efforts from the medical community.
The outlook for this CD7 CAR-T cell therapy is promising, especially for AML patients who have undergone various treatments and allogeneic hematopoietic stem cell transplants. We look forward to more in-depth research and treatment outcomes in the future, offering more beneficial treatment choices for long-term survival among patients.
(source: ClinicalTrials.gov registration number NCT04938115
Preliminary results published by Professor Lu Peihua and their team in a top-tier journal)
#AMLResearch #CancerTreatment #CARTTherapy #Leukemia #MedicalBreakthrough #Cancer #AML #Immunotherapy #ClinicalTrials #BloodCancer #PatientCare #HealthcareAdvances #PrecisionMedicine #ScienceAndHealth #MedicalScience #CancerSurvivor #AMLWarriors #ResearchProgress #CancerFree #HopeInTreatment #acutemyeloidleukemia